Simple Skin Swab Could Help Predict Future Eczema Risks in Kids

Researchers have found that physicians can predict the future risk of eczema in children via simple skin swabs. Their findings show that collecting cells from the top layers of a week-old baby’s skin using sticky strips can allow doctors to predict whether the infant will develop eczema.

Atopic dermatitis (AD) is the most common type of eczema. It is characterized by itchy, dry and inflamed skin. While it can occur at any age, the condition is very common in young children.

The condition also increases a patient’s risk of developing asthma, hay fever and food allergies. It affects close to 30% of children across the globe and can have a significant impact on the quality of life of affected people and their families.

Donald Leung, senior researcher and head of pediatric allergy and clinical immunology at the National Jewish Center, says that the best way to deal with AD is to avoid it as it tends to recur even after treatment. The researchers analyzed the levels of lipids and cytokines in the outermost layer of the epidermis (stratum corneum) to identify if children would develop atopic dermatitis when they were two years old.

After collecting stratum corneum samples from more than 100 two-month-old babies using skin tape strips, the researchers sought to identify biomarkers that show the probability of developing AD later in life. They used liquid chromatography-electrospray ionization tandem mass spectrometry to analyze the samples for lipid molecules. The samples also underwent cytokine analysis to give researchers a deeper understanding of the mechanisms behind local immune responses and skin barrier function.

Of the 74 babies who were at risk of developing AD due to family history, 29.7% developed AD by the time they were two years old. On the other hand, only 13.5% of the 37 babies who were not at risk developed atomic dermatitis.

All of the infants who later developed atopic dermatitis had considerably reduced levels of protein-bound ceramides and high levels of alpha-hydroxy fatty acid sphingosine ceramides“short-chain” non-hydroxy and unsaturated sphingomyelin species. Additionally, interleukin (IL-)13 and thymic stromal lymphopoietin (TSLP) levels were up by 78.3% and 74.5% respectively.

Overall, the researchers found that family history in combination with skin biomarkers could allow physicians to predict the later development of AD with relative accuracy. They said that the combination of the two would give clinicians “unprecedented powers of prediction” and allow for more precise treatments for atopic dermatitis.

The study’s findings were published in the “Journal of Allergy and Clinical Immunology.”

For individuals who are already experiencing atopic dermatitis, the future may be brighter as entities such as Jupiter Wellness Inc. (NASDAQ: JUPW) finalize and bring to market the superior topical treatments that they have been developing.

NOTE TO INVESTORS: The latest news and updates relating to Jupiter Wellness Inc. (NASDAQ: JUPW) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050